relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells by Ricca, A et al.
The mammalian nuclear factor-kappa B (NF-kB) family com-
prises 5 members (p50, p52, relA/p65, c-rel and relB) which form
a different array of homo-and hetero-dimers and are regulated by a
group of citoplasmic inhibitors (I Bs) (Krappmann et al, 1999). In
unstimulated cells, it is retained in an inactive cytoplasmatic form
by one of several I B molecules. Activation of NF-kB complexes
by a variety of stimuli results in the phosphorylation and rapid
degradation of I Bs through the ubiquitin-proteasome pathway
(Thanos and Maniatis, 1999). Dissociation of I B from NF-kB
allows NF-kB to translocate to the nucleus and bind to  B DNA
sites with the consequent activation of  B-target gene expression
(Baeuerle and Henkel, 1994). 
The rel/NF-kB/I B superfamily of signal transducers and tran-
scription factors exists in virtually all cell types but has been char-
acterized as a mediator of response to several stimuli in the
immune system (Baeuerle and Henkel, 1994; Krappmann et al,
1999; Thanos and Maniatis, 1999). More recently, it has been
shown that NF-kB can also regulate diverse cellular processes
such as apoptosis (Abbadie et al, 1993; Lin et al, 1995; Carter et al,
1996; Grilli et al, 1996; Grimm et al, 1996; Wang et al, 1998; Wu
et al, 1998; Pahl, 1999; Lin et al, 1999; Grilli and Memo, 1999;
Kaltschmidt et al, 2000), cell cycle (Baeuerle and Baltimore, 1996;
Bargou et al, 1997; Bash et al, 1997; Seitz et al, 1998; Sheehy and
Schlissel, 1999) and oncogenesis (Higgins et al, 1993; Gilmore,
1997; Nakshatri et al, 1997; Sovak et al, 1997; Visconti et al, 1997;
Rayet and Gélinas, 1999; Andela et al, 2000; Huang et al, 2000). 
A variety of studies encompassing a broad range of both cell
types and apoptosis-inducing stimuli have evidenced that activation
of NF-kB plays a role in both protecting and inducing apoptosis. In
a number of systems, NF-kB has been demonstrated to have an anti-
apoptotic function, and several NF-kB responsive anti-apoptotic
genes (clAP1, clAP2, TRAF1, TRAF2, IEXL-1) have recently been
identified and claimed to play a role in this process (Wang et al,
1998; Wu et al, 1998; Pahl, 1999). Activation of NF-kB has also
been correlated with the activation of the apoptotic programme in a
wide variety of systems such as avian embryonic development,
ceramide-activated osteoblasts, dopaminergic neurons derived from
Parkinson disease patients, bone marrow cells and prostate carci-
noma cells (Abbadie et al, 1993; Lin et al, 1995,1999; Carter et al,
1996; Grilli et al, 1996; Grimm et al, 1996). The pro- and anti-
apoptotic regulatory function of NF-kB has been shown to depend
on the cell type, the differentiation state of the cell, and the nature
of the apoptotic stimulus (Abbadie et al, 1993; Lin et al, 1999;
Kaltschmidt et al, 2000). Given such a divergent outcome, it has
been suggested that NF-kB activation acts as a checkpoint between
cell rescue and apoptosis (Grilli and Memo, 1999). 
As reported for the NF-kB role on apoptosis, a different effect
on cell proliferation has also been demonstrated. In fact, in con-
trast to its role in HeLa cells and in a transformed pro-B cell line
where NF-kB leads to growth arrest, and in transgenic epithelium
where it produces hypoplasia, NF-kB proteins promote cellular
proliferation in malignant lymphoma (Baeuerle and Baltimore,
1996; Bargou et al, 1997; Bash et al, 1997; Seitz et al, 1998;
Sheehy and Schlissel, 1999). 
Thus, the cell type and the context of a NF-kB-inducing stim-
ulus appear to be crucial in determining the outcome of a signal
that can lead to proliferation, differentiation or cell death. 
Persistent nuclear NF-kB activity has been described in several
human cancer cell types, where chromosomal amplification, over-
expression and rearrangement of genes coding for rel/NF-kB
factors have also been outlined. A continuous activation of NF-kB
factor is emerging as an indicator of various types of solid tumours
relA over-expression reduces tumorigenicity and
activates apoptosis in human cancer cells 
A Ricca1, A Biroccio1, D Trisciuoglio1, M Cippitelli2,3, G Zupi1 and D Del Bufalo1
1Experimental Chemotherapy Laboratory and 2Laboratory of Pathophysiology, Regina Elena Cancer Institute, Via delle Messi d’Oro 156, 00158 Rome, Italy;
3Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy 
Summary We previously demonstrated that bcl-2 over-expression increases the malignant behaviour of the MCF7 ADR human breast
cancer cell line and enhances nuclear factor-kappa B (NF-kB) transcriptional activity. Here, we investigated the direct effect of increased NF-
kB activity on the tumorigenicity of MCF7 ADR cells by over-expressing the NF-kB subunit relA/p65. Surprisingly, our results demonstrated
that over-expression of relA determines a considerable reduction of the tumorigenic ability in nude mice as indicated by the tumour take and
the median time of tumour appearance. In vitro studies also evidenced a reduced cell proliferation and the activation of the apoptotic
programme after relA over-expression. Apoptosis was associated with the production of reactive oxygen species, and the cleavage of the
specific substrate Poly-ADP-ribose-polymerrase. Our data indicate that there is no general role for NF-kB in the regulation of apoptosis and
tumorigenicity. In fact, even though inhibiting NF-kB activity has been reported to be lethal to tumour cells, our findings clearly suggest that an
over-induction of nuclear NF-kB activity may produce the same effect. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: relA; breast carcinoma; tumorigenicity; apoptosis 
1914
Received 17 April 2001 
Revised 24 August 2001 
Accepted 25 September 2001 
Correspondence to: D Del Bufalo
British Journal of Cancer (2001) 85(12), 1914–1921
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2174, available online at http://www.idealibrary.com on  http://www.bjcancer.comrelA effect on tumorigenicity 1915
British Journal of Cancer (2001) 85(12), 1914–1921 © 2001 Cancer Research Campaign
(Gilmore, 1997) and as an important factor in the onset and
progression of several human tumours including breast carcinoma
(Bargou et al, 1997; Visconti et al, 1997; Rayet and Gélinas, 1999;
Huang et al, 2000). Breast cancer cell lines, breast cancer speci-
mens and a majority of carcinogen-induced mammary tumours in
rats exhibit high levels of nuclear NF-kB DNA-binding activity,
and a link has been suggested between constitutive activation
of NF-kB and tumour progression to the more aggressive anti-
oestrogen-resistant phenotype and in general with the acquisition
of invasive-metastatic properties (Higgins et al, 1993; Nakshatri
et al, 1997; Sovak et al, 1997; Andela et al, 2000). 
However, little is known about how constitutive NF-kB activity
contributes to the malignancy of cancer cells. Several studies,
demonstrating that NF-kB activity contributes to cell survival and
abnormal cell proliferation of tumour cells, seem to indicate that
rel transcription factor may provide accessory functions for cancer
development. 
We have previously shown that the increase of tumorigenic,
metastatic and angiogenic potential of the MCF7 ADR human
breast cancer cell line in consequence of bcl-2 over-expression is
associated with an enhanced NF-kB-mediated transcriptional
activity (Del Bufalo et al, 1997; Biroccio et al, 2000; Ricca et al,
2000). Here, we investigated the direct role of NF-kB sustained
over-induction on the tumorigenesis of the MCF7 ADR cell line.
These cells were transfected with an expression vector for relA and
3 stable clones over-expressing relA were utilized for in vitro
studies and evaluation of tumorigenic potential in nude mice. We
found that the constitutive relA over-expression in MCF7 ADR
cells results in inhibition of tumorigenic ability, associated with re-
duced cell proliferation and activation of the apoptotic programme.
MATERIAL AND METHODS 
Cell lines and culture conditions 
The MCF7 ADR human breast cancer, the M14 melanoma and the
H460 lung adenocarcinoma lines were maintained in RPMI 1640
supplemented medium (Gibco, Gaithersburg, MD, USA). MCF7
ADR cells were cultured in 10 µ M Adriamycin (ADR), and grown
for 2 weeks in drug-free medium prior to each experiment. Cell
growth was assessed by seeding 2 × 105 cells in 60-mm plates
(Nunc, Mascia Brunelli, Milan, Italy). Cell counts (Coulter Counter,
Kontron Instruments, Milan, Italy) and viability (trypan blue dye
exclusion) were determined daily, from day 1 to day 8 of culture. 
Transfection 
Cells (~1 × 106 cells in 250 µ l medium) were transfected by electro-
poration (280 V, 950 µ F, Gene Pulser, Bio-Rad, Milan, Italy) with
the expression vector pcDNA3 (Invitrogen BV, NV Leek, The
Netherlands) carrying the relA cDNA and the gene for resistance to
Neomicine (neo, Gibco). As control, cells were transfected with the
plasmid carrying the neo-resistance gene alone. Transfected clones
were collected 20 days after selection in neo-containing medium
(800 µ g ml–1) and relA expression was tested by Western blotting on
nuclear extracts obtained as previously reported (Ricca et al, 2000). 
Western blotting 
To evaluate the expression of relA, p53, bcl-2, bax, bcl-xL/S, 
c-myc and Fas-Ligand (Fas-L) proteins or the cleavage of Poly-
ADP-ribose-polymerrase (PARP) substrate total cells or nuclei
were incubated at 4˚C for 30 min in lysis buffer with ionic deter-
gent (2% SDS; 20 mM Tris pH 8.0; 2 mM PMSF). 40 µ g of
nuclear extracts or total proteins from each sample were separated
by SDS-PAGE. Western blot and detection were performed as previ-
ously reported (Del Bufalo et al, 1996). Antibodies specific for
human p65 (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA;
dil. 1:5000), p53 (clone Pab 1801; Santa Cruz Biotechnology; dil.
1:500), c-myc (clone 9E10; Santa Cruz Biotechnology; dil. 1:1000),
PARP (VIC 5; Boehringer Mannheim, Germany; dil. 1:2000), bcl-2
(clone 124; Dako SA, Glostrup, Denmark; dil. 1:200), bcl-xL/S (S-18;
Santa Cruz Biotechnology; dil 1:500); Fas-L (N-20; Santa Cruz
Biotechnology; dil. 1:1000), bax (N20; Santa Cruz Biotechnology;
dil 1:500) were used. Peroxidase-labelled anti-mouse and anti-rabbit
(Amersham Pharmacia Biotech; Milan, Italy, dil. 1:10 000) were
used according to the manufacturer’s instructions. To check the
amount of proteins transferred to nitrocellulose membrane, heat
shock protein (HSP) was used as control and detected by an anti HSP
72/73 mAb (Ab-1, clone W27, Calbiochem, Cambridge, MA, USA).
The relative amount of the transferred proteins was quantified by
scanning the autoradiographic films with a gel densitometer scanner
(Bio-Rad) and normalized to the related HSP 72/73 amounts. 
CAT assay 
NF-kB- and p53-mediated transcriptional activity was evaluated
by CAT assay using the 4X(NF-kB)tkCAT and PG13-CAT
reporters respectively, as previously described (Biroccio et al,
1999; Ricca et al, 2000). To evaluate p53-mediated transcriptional
activity, CAT assay was performed on MCF7 ADR cells 12 h after
5 µ g ml–1 cisplatin (DDP) or 15 µ M ADR treatment, and on H460
cells 12 h after exposure to 1 µ M ADR. 
Transfection of cells was carried out by electroporation in the
presence of 15 µ g of CAT reporter genes and 4 µ g of β -galactosidase
(β -gal) expression vector PEQ176 to measure transfection effi-
ciency. 48 h after transfection proteins were extracted by 3 cycles
of rapid freezing and thawing. Protein concentration was quanti-
fied using the bicinchoninic acid protein assay reagent (BCA,
Pierce, Chemical Co, Rockford, IL). CAT activity in equal num-
bers of β -gal units from different transfections was measured by
using 14C-chloramphenicol and acetyl coenzyme A. Acetylated chlo-
ramphenicol was separated from non-acetylated chloramphenicol
by thin-layer chromatography and quantified after autoradiog-
raphy by means of slide scanner (Bio-Rad). 
Cytofluorimetric analysis 
The percentage of cells in the different phases of cell cycle and in the
sub-G1 peak was estimated as previously described (Del Bufalo et al,
1996) using a CELLQuest software (Becton Dickinson, Heidelberg,
Germany). For the analysis of reactive oxygen species (ROS)
production, cells were collected, assayed for viability by trypan blu
dye exclusion and then incubated for 45 min at 37˚C with 4 µ M
dihydroethidium (DHE, Molecular Probes, Eugene, OR, USA).
Cytofluorimetric analysis was performed at the end of DHE staining. 
Terminal deoxynucleotide transferase (TdT)-mediated
dUTP nick-end labelling (TUNEL) 
The immunochemical detection of apoptotic cells was performed
by TUNEL assay using the in situ cell death detection kit
(Boehringer Mannheim), as previously reported (Leonetti et al,1916 A Ricca et al 
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1999). Briefly, 50 µ l of TUNEL reaction mixture was applied to
the cytospin preparation and the incubation performed at 37˚C for
60 min. The slides were then washed 3 times in PBS for 5 min,
stained with Hoechst and examined by fluorescence microscope. 
Evaluation of tumorigenicity in athymic mice 
6–8-week-old female CD-1 nude (nu/nu) mice, purchased from
Charles River Laboratory (Calco, Italy) were used. All procedures
involving animals and their care were described previously and
were in accordance with national and international laws and poli-
cies (Leonetti et al, 1999). Each experimental group included
10 animals. To assess in vivo tumorigenicity we injected into the
hind leg muscles of the mice different numbers of viable tumour
cells (from 5 × 105 to 2 × 107). Mice were observed daily to estab-
lish the tumour take, the median time of tumour appearance and
the tumour weights as reported previously (Leonetti et al, 1999).
The results were analysed by the Mann–Whitney U test for
statistical significance. Differences were considered significant at
P values < 0.05 (2-sided). 
RESULTS 
Generation of relA over-expressing clones 
A mammalian expression vector for relA was used for generation of
stable transfectants from MCF7 ADR line. 3 clonal cell lines stably
over-expressing relA (AP2, AP3, AP14) and a APneo control clone,
transfected with the vector carrying only the neo-resistance gene,
were chosen for the experiments. Figure 1A shows Western blot
analysis on nuclear extracts of relA/p65 protein levels in the MCF7
ADR line, APneo, AP2, AP3 and AP14 clones. Densitometric
analysis normalized to HSP 72/73 expression reveals about 4–5-fold
average increase of nuclear relA expression in all relA transfectants
if compared to the levels observed in MCF7 ADR parental cells.
The transfection with the control vector did not produce any change
in relA nuclear levels. To investigate whether the relA over-
expression was competent for transactivation. NF-kB-mediated
transcriptional activity was evaluated. For this purpose CAT assay
using a CAT reporter gene under the control of 4 copies of the IL-6
NF-kB-binding element was performed in the 3 relA transfectants,
APneo clone and in parental cells. Figure 1B shows that the CAT
activity, almost identical in the parental cell line and the APneo
control clone, is up-regulated by relA over-expression in all the relA
transfectants. Densitometric analysis revealed that the ratio between
acetylated and unacetylated 14C-cloramphenicol (CAT activity), is
about 6-fold higher in all relA clones compared to control cells. This
result indicates that the stable increase of nuclear relA protein levels
obtained in relA transfectants confers a corresponding increase in
NF-kB-mediated transcriptional activity. 
Tumorigenicity of relA transfectants 
To evaluate whether over-expression of relA might modify tumori-
genicity of MCF7 ADR, different numbers of MCF7 ADR, APneo,
AP2, AP3 and AP14 cells were injected intramuscularly into nude
mice and tumour take and median time of tumour appearance were
assessed (Table 1). For inoculum size ranging from 2 × 107to 5 × 105
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Figure 1 (A) Western blot analysis of the p65 protein in the nuclear lysates
of MCF7 ADR line, APneo control clone and 3 relA over-expressing clones
(AP2, AP3, AP14). The relative amount of the transferred relA protein was
quantified and normalized to the corresponding HSP 72/73 protein amount.
(B) NF-kB-mediated transcriptional activity of MCF7 ADR line, APneo control
clone and 3 relA over-expressing clones (AP2, AP3, AP14) evaluated by
CAT assay 
Table 1 Tumorigenicity of MCF7 ADR, APneo control clone, and AP2, AP3,
AP14 relA transfectants 
No. of  Tumour takea Tumour 
cells  (mice with tumours/mice  latencya
injected injected) (days) 
MCF7 ADR 2 × 107 6/6 8 
1 × 107 6/6 10 
5 × 106 6/6 15 
1 × 106 6/6 20 
5 × 105 6/6 32 
APneo 2 × 107 6/6 8 
1 × 107 6/6 10 
5 × 106 6/6 15 
1 × 106 6/6 20 
5 × 105 6/6 32 
AP2 2 × 107 4/6 38 
1 × 107 3/6 39 
5 × 106 1/6 NAb
1 × 106 0/6 NA 
5 × 105 0/6 NA 
AP3 2 × 107 4/6 39 
1 × 107 3/7 43 
5 × 106 2/8 NA 
1 ×  106 0/7 NA 
5 ×  105 0/7 NA 
AP14 2 ×  107 3/5 38 
1 ×  107 2/5 43 
5 ×  106 1/5 NA 
1 ×  106 0/7 NA 
5 ×  105 0/7 NA 
aTumour take and tumour latency were analysed until day 45 after cell
injection. bNA = not assessable.cells, parental and neo-transfected cells resulted in tumours in all the
animals injected. Whereas, the injection of 2 × 107 relA over-
expressing cells resulted in tumours in only 60–67% of animals.
Tumour take of relA transfectants decreases to values of 40–50%
and 17–25%, respectively, when 1 × 107 and 5 × 106 relA over-
expressing cells were injected. 45 days after injection no tumours
were observed in mice injected with 1 × 106 and 5 × 105 relA cells.
The analysis of the median time of tumour appearance revealed that
mice injected with 2 × 107 relA over-expressing cells began to
develop tumours 38 days after injection, whereas the same number
of parental and neo-transfected cells resulted in tumours after only 8
days (P = 0.0095). Consequently, tumour volumes 45 days after
injection of 2 × 107 relA over-expressing cells were significantly
smaller (mean tumour weight = 157 ±19 mg) than those obtained by
injections of the same number of parental and neo-transfected cells
(mean tumour weight = 663 ± 86 mg) with P value of 0.0012. 
In vitro cell proliferation and cell cycle distribution of
relA transfectants 
Since relA and other members of the rel/NF-kB family have been
demonstrated to affect proliferation of different model systems
(Bash et al, 1997; Sheehy and Schlissel, 1999), we investigated the
effects of the relA over-expression on cell growth and cell cycle
distribution. Figure 2A shows the growth curves of the APneo
control clone and 2 relA over-expressing clones. It appears evident
that during the exponential phase of growth, relA over-expressing
clones show a slight reduction in cell proliferation, when
compared to the APneo clone. Moreover, a different saturation
density characterized relA transfectants from neo-transfected cells.
In fact, the mean cell number to reach the saturation density is 1.2
× 106 and 2.8 × 106 for relA transfectants and APneo clone, respec-
tively. In addition, at day 7 of growth a decrease in cell number is
observed in relA transfectants, while neo-transfected cells remain
in the plateau phase of growth. Figure 2B illustrates APneo, AP2
and AP14 cell distribution in the different phases of the cell cycle.
The analysis, performed from day 4 to 7 of growth curve, demon-
strated an accumulation of relA overexpressing cells at the G1
phase of cell cycle, already evident at day 4, with a concomitant
decrease in the percentage of cells in S compartment. The relA
over-expression did not affect the number of cells in the G2/M
phase. Results obtained from the analysis of the MCF7 ADR line
and the AP3 clone were similar to those obtained, respectively, for
APneo and AP14 clones (data not shown). 
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Figure 2 In vitro cell proliferation (A) and cell cycle distribution (B) of APneo control clone (  ), AP2 (  ) and AP14 (   ) relA transfectants. The data are the
mean of 3 independent experiments with standard deviation Effect of relA over-expression on apoptotic cell death 
Since NF-kB is involved in the regulation of apoptosis in several
systems (Lin et al, 1995, 1999; Kaltschmidt et al, 2000), the reduc-
tion in cell number observed during cell growth and the decrease
in tumorigenicity observed in relA transfectants led us to hypothe-
size that NF-kB activity could be involved in apoptosis induction.
With this aim, we carried out a cytofluorimetric assessment of the
DNA content, checking for the appearance of the sub-G1 apoptotic
population during the in vitro culture of control cells and relA
transfectants. As reported in Figure 3A no cells with a DNA
content lower than diploid appear from the analysis of APneo cells
while a well-defined sub-G1 population is evident in AP2 and
AP14 clones at day 6 of the growth curve. The percentage of hypo-
diploid cells is about 35% in both AP2 and AP14 clones. When
the same analysis was performed at day 8 of cell culture the
percentage of hypo-diploid cells was more than 80% for AP2 and
AP14 cells, and only 10% for control cells (data not shown).
TUNEL assay (Figure 3B) performed at day 6 of cell culture
confirmed the cytofluorimetric data, demonstrating the presence
of apoptotic cells both in AP2 and AP14 clones and the absence in
APneo control cells. Results obtained from the analysis of the
MCF7 ADR line and the AP3 clone were similar to those obtained,
respectively, for APneo and AP14 clones (data not shown). 
Effect of relA over-expression on apoptosis-related
protein expression 
To identify molecular events which may account for the NF-
kB-induced apoptosis described above, we examined whether the
product of genes, involved in the regulation of the apoptotic
process, such as c-myc, p53, bcl-xL/S, bcl-2, bax, Fas-L, was modu-
lated after relA over-expression. While we were unable to find
significant changes in c-myc, bax, bcl-2, bcl-xL and Fas-L expres-
sion between control cells and relA transfectants, Western blot
analysis of p53 protein revealed an increase of p53 protein levels
of about 4–5-fold when relA over-expressing cells were compared
to control cells (Figure 4). bcl-xS protein was not detected in our
experimental conditions (data not shown). 
The high level of p53 shown by Western blot analysis in the
MCF7 ADR cells and the lack of activation of bax protein in relA
transfectants expressing higher level of p53 than the parental line,
led us to hypothesize that MCF7 ADR cells possess mutated p53
protein. Thus, the p53 transcriptional activity over a p53-specific
promoter was evaluated by CAT assay after exposure to DDP and
ADR, 2 genotoxic damage-inducing agents. Figure 5 shows that
the activity of the PG13-CAT reporter gene is undetectable both in
untreated and DDP- or ADR-treated cells demonstrating that
endogenous p53 was devoid of transcriptional activity. 
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Effect of relA over-expression on ROS production 
Since a strong correlation between NF-kB activation and ROS-
induced apoptosis has recently been demonstrated (Dumont et al,
1999), we evaluated the intracellular content of ROS in control
and relA over-expressing cells (Figure 6A). Gating the viable cells
by means of forward- and side-scatter values assessment, no
change in the relative fluorescence for APneo clone was observed
at day 5 of the growth curve, while a clear increase in fluorescence
is evidenced in AP2 and AP14 clones, the percent of cells with
high-ROS content being 52% and 66%, respectively. 
As a final biochemical event of apoptotic cell death, the cleavage
of PARP substrate was evaluated. Figure 6B shows the results of
Western blot analysis on total protein lysates from APneo, AP2 and
AP14 clones. 116 kDa PARP was detected in lysates from both neo-
and relA transfectants, while the 85 kDa cleavage product was only
observed in lysates from the relA transfectants. 
All the results obtained in AP2 and AP14 were similar to those
observed in the AP3 clone (data not shown). No difference
between the MCF7 ADR parental cells and the APneo clone were
observed (data not shown). 
Effect of relA over-expression on apoptotic cell death
of melanoma cells 
To examine whether NF-kB increased activity through relA over-
expression results in the induction of apoptosis in another tumour
cell line other than in MCF7 ADR model, we transfected the M14
human melanoma cell line with the same relA expression vector
used for MCF7 ADR cell transfection. Parental cells, a relA over-
expressing clone (MRel2) and a relA over-expressing mixed popu-
lation (M14MIX) were studied to evaluate the induction of
apoptosis by means of cytofluorimetric measure of DNA content.
As shown in Figure 7 only relA over-expressing cells, either from
the clonal or the mixed population, undergo apoptotic cell death as
revealed from the clear appearance of the characteristic hypo-
diploid peak. The share of hypo-diploid cells is 25% and 40% for
M14MIX and MRel2 clone, respectively. These data confirmed
and extended our previous observation obtained on MCF7 ADR
cells, attesting for a more general phenomenon which links
induced activation of NF-kB and apoptosis in human tumour cells. 
DISCUSSION 
We recently demonstrated that the increased tumorigenic, metastatic
and angiogenic potential induced by bcl-2 over-expression in the
MCF7 ADR human breast cancer cell line, is accompanied by the
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enhancement of NF-kB transcriptional activity (Del Bufalo et al,
1997; Biroccio et al, 2000; Ricca et al, 2000). 
In this paper we investigated the direct effects of an increased
constitutive NF-kB activity on the malignant behaviour of MCF7
ADR cells by over-expressing the NF-kB subunit relA/p65. 
Surprisingly, we found that a sustained activation of NF-kB
leads to a great reduction of the MCF7 ADR tumorigenic potential
in nude mice. In fact, the injection of 5 × 105 parental cells results
in tumours in all the animals, while no animals developed tumours
when injected with the same number of relA over-expressing cells.
In addition, 2 × 107 control cells give rise to tumours in a very
short time (8 days), while the same number of relA transfected
cells gives rise to tumours in only 4/6 mice and the tumour latency
was more then 4 times longer than that of MCF7 ADR tumours.
The decrease in tumorigenicity was accompanied by a reduction of
in vitro cell proliferation. Our data are in agreement with those of
other authors demonstrating that elevated levels of relA induced a
G1 cell cycle arrest (Sheehy and Schlisse, 1999). Also the over-
expression of other members of the rel/NF-kB, such as c-rel has
been found to induce growth arrest at the G1/S-phase transition
(Bash et al, 1997). Finally, studies performed on murine and
human epidermis transgenic for proteins activating or inhibiting
NF-kB function, demonstrated that NF-kB function is important
for cellular growth inhibition in stratified epithelium (Seitz et al,
1998). 
We also found that the decreased tumorigenicity was associated
with activation of the apoptotic programme. The ability of NF-kB
to induce apoptosis was also observed in M14 human melanoma
cell line. 
To address the molecular and biochemical events responsible
for the NF-kB-induced apoptosis, we investigated the involvement
of some apoptosis-modulator proteins. No difference between
parental cells and relA transfectants was found in the expressions
of Fas-L, bcl-2, bcl-xL, bax and c-myc proteins, thus, indicating
these proteins were not involved in NF-kB-induced apoptosis. On
the contrary, the p53 protein, whose gene is known to be a target of
NF-kB transcriptional activity (Wu and Lozano, 1994), was found
to be increased after relA over-expression. However, we have
evidence that p53 is devoid of transcriptional activity, indicating
that the mechanisms responsible of p53 inactivation are able to
block also high level of p53. Thus, even though mutant p53 gain of
function has been demonstrated (Blandino et al, 1999), NF-kB-
mediated apoptosis in MCF7 ADR cells is probably independent
of this protein. The inability of p53 to increase bax levels in relA
transfectants and our previous results, demonstrating that p53 is
segregated in the cytoplasm in spite of the wild-type configuration
(Del Bufalo et al, 1996), support the evidence that p53 is in an
inactivated form. 
Our data provide evidence that the massive apoptotic cell death
induced by relA overexpression is associated to ROS generation.
In fact, a significant percentage of ROS production is exclusively
observed in the relA transfectants. This is in agreement with other
findings demonstrating that ROS per se are potent inducers of
apoptosis (Kroemer et al, 1997) and that the hydrogen peroxide-
induced apoptosis, requires the release of mitochondria-derived
ROS and the activation of NF-kB (Dumont et al, 1999). 
In addition, our results, demonstrating the ability of p65 over-
expression to induce apoptosis, are in agreement with published
data evidencing NF-kB implication in inducing cell death in
certain cells such as neurons, Schwann cells, prostate carcinoma
cells, and embryonic kidney cells (Lin et al, 1995; Carter et al,
1996; Grilli et al, 1996; Grimm et al, 1996; Lin et al, 1999). As
suggested by Arlt, the fact that NF-kB activation triggers apoptosis
might involve particular NF-kB target genes that are of functional
duality in terms of growth control and survival and that are subject
to modulation by many other cellular signals (Arlt et al, 2001).
Moreover, even though some papers evidenced the NF-kB ability
to protect against instead of triggering apoptosis, the majority of
these results demonstrated the anti-apoptotic role of NF-kB in
response to the induction of apoptosis by different stimuli (Carter
et al, 1996; Grilli et al, 1996; Grimm et al, 1996; Kaltschmidt et al,
2000). On the contrary, in our model we evaluated the effect of
NF-kB over-expression in the absence of stimuli inducing apop-
tosis. Moreover, even though a few studies have demonstrated
reduced cell growth, adhesion and in vivo tumour growth by anti-
sense inhibition of the p65 subunit (Kitajima et al, 1992; Higgins
et al, 1993; Khaled et al, 1996), some authors disputed the speci-
ficity of these effects (Andela et al, 2000), and other authors found
the lack of an effect of NF-kB suppression on in vivo tumour
growth (Khaled et al, 1996). 
The data presented in this paper appear to be in contrast to that
previously published by our group where bcl-2 over-expression in
MCF7 ADR cells enhances NF-kB activity and increases the
tumorigenic, metastatic and angiogenic potential (Del Bufalo et al,
1997; Biroccio et al, 2000; Ricca et al, 2000). We suggest that in
the complex onset and progression of human cancers, amplifica-
tion and over-expression of cellular rel/NF-kB genes are likely to
provide the necessary threshold for nuclear rel/NF-kB activity. As
the enhancement in NF-kB activity results in activation of the
apoptotic programme and on the basis of the data presented here, we
can speculate that MCF7 ADR cells over-expressing bcl-2 balances
the pro-apoptotic NF-kB property with the anti-apoptotic activity of
bcl-2. In addition, we have evidence that bcl-2 acts, through modu-
lation of other factors (Del Bufalo et al, 1997), other than through
NF-kB activation (Ricca et al, 2000), thus, suggesting that bcl-2
might modulate the transcription activity of other factors that are
responsible for the phenotype observed after bcl-2 over-expres-
sion. As such, the increase of NF-kB activity following bcl-2 or
p65 over-expression may represent 2 different stimuli for MCF7
ADR cells, the first increasing tumorigenicity and the second one
inducing apoptosis and reducing tumorigenicity. It is also possible
that the levels of NF-kB activity play a role in this phenomenon. In
fact, the indirect increase in NF-kB transcriptional activity induced
by bcl-2 overexpression (about 3 times greater in bcl-2 transfec-
tants than the parental line) corresponds to lower levels of those
obtained directly increasing NF-kB activity by transfection (about
6 times greater in bcl-2 transfectants than the parental line). As
suggested by Gilmore, partial induction of nuclear NF-kB activity
may be protective, while full induction of NF-kB activity may itself
be toxic or may induce apoptosis (Gilmore, 1997). Thus, over-
induction of nuclear NF-kB activity may be as lethal to tumour
cells as inhibition of this activity. 
In conclusion, the data presented in this paper add new insights
to the complex linkage between the NF-kB activity and the regula-
tion of the apoptotic process and tumorigenic potential. However,
it is clear that there is no general role for NF-kB in the regulation
of apoptosis and tumorigenicity but rather NF-kB functions as
a complex cell-specific and stimuli-specific regulator of this
phenomenon. Any use of effective interventions against cancer,
targeting NF-kB signalling will rely on a full understanding of the
role of cell type, NF-kB subunit composition, target gene functions
and promoter sensitivity to NF-kB. relA effect on tumorigenicity 1921
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